N/A
N=4
Feasibility - Infinitome
Alzheimer Disease
Bottom Line
View on ClinicalTrials.gov: NCT04563767 ↗Enrolled (actual)
4
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Number of Participants Who Completed Rs-fMRI — 4 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Infinitome (Procedure)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- HealthPartners Institute
- Primary completion
- Oct 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Completed Rs-fMRI |
4 | — |
| PRIMARY Number of Subjects Whose Images Completed Analysis |
4 | — |
Summary
The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. The potential of Infinitome in identifying connectome dysfunction for neurodegenerative diseases such as Alzheimer's disease has yet to be explored. This diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.
Eligibility Criteria
Inclusion Criteria
- Patients with a diagnosis of mild, moderate, or severe Alzheimer's disease
- Age: 40 - 90 Years
- Patients who are clinically indicated for an MRI
Exclusion Criteria
- fMRI contraindicated (eg. Implantable device, pacemaker, metallic implants, etc.)
- Subject unable to tolerate sitting for a one hour fMRI
- Other concerns as determined by the investigator
Data sourced from ClinicalTrials.gov (NCT04563767). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.